Skip to main content
23 Sep 2015

Towards a cure for Type 1 diabetes

Garvan immunologist Associate Professor Shane Grey and collaborators from other institutions have been awarded $3.3 million to extend their innovative research towards a cure for Type I diabetes. The researchers aim to make islet transplantation a feasible therapeutic option for more individuals with Type I diabetes, including children.

Associate Professor Shane Grey, of Sydney’s Garvan Institute of Medical Research, together with collaborators from the Westmead Millennium Institute for Medical Research and the Children’s Hospital at Westmead, have been awarded $3.3 million to extend their innovative research towards a cure for Type I diabetes. The grant was awarded by the Type 1 Diabetes Clinical Research Network (T1DCRN), an innovative clinical research program led by the Juvenile Diabetes Research Foundation (JDRF Australia) and supported by the Australian Research Council.

The researchers aim to make significant improvements in the outcome of islet transplantation therapy (see below), making it a clinically realistic and attractive therapeutic option for more individuals with Type 1 diabetes, including children.

Their approach focuses on calming the immune response of patients to islet transplantation. The strategy may make it possible for treated individuals to live drug-free in the long term.

In Type 1 diabetes, the body destroys the cells within the pancreas that produce insulin. Without insulin to mastermind the uptake of sugar from the blood, glucose levels can rapidly become damagingly high or plummet to life-threatening lows.

Islet transplantation therapy – in which insulin-producing structures called islets, derived from donor pancreas, are transplanted into the recipient’s liver – can cure individuals of diabetes by restoring glucose-responsive insulin production. However, recipients must take powerful immunosuppressive drugs for the rest of their lives to avoid the introduced islets coming under attack from their own immune system.

A/Prof Grey says, “Islet transplantation therapy has had a big impact on the lives of people with Type 1 diabetes who also experience a dangerous condition called hypoglycemic unawareness. But the need to use immunosuppressive drugs stops us from being able to give this promising therapy to more people with Type 1 diabetes, including children.”  

A/Prof Grey’s team has discovered that the transplanted islet cells provoke and encourage the immune attack that they are subjected to. Members of his research group, particularly PhD graduate Nathan Zammit, have pioneered research into how factors intrinsic to islets affect whether they transplant successfully.

This work led to the development of the idea of the ‘death-defying islet’ – an islet for transplantation that could be protected from immune attack by modulating the molecular signals it emits.

In research funded by the grant, A/Prof Grey will determine whether engineering islets to produce more of the anti-inflammatory protein A20 can improve the function of islets after transplantation, decrease the need for immunosuppressive therapies and improve overall success rates.

“We know from Nathan Zammit’s extensive PhD studies on A20 that this protein has remarkable properties in pancreatic islets,” A/Prof Grey explains. “Nathan showed that it ‘calms’ the islets by inhibiting key inflammatory pathways within the islet cells – and he showed that it has a strong positive effect on the function of transplanted islets.

“More than that, we have observed that A20 also promotes immune tolerance to the introduced islets. The challenge now is to explore whether this protein can exert these powerful effects in the clinic, leading to improved immune tolerance to islet transplantation.”

A/Prof Grey can’t wait to get started. He says, “This is a fantastic opportunity to make a real difference to people with Type 1 diabetes and completely do away with the need for immunosuppression. And if we are successful one could imagine this new approach could be extended to other types of transplants and possibly used for the treatment of autoimmune conditions.”

A/Prof Grey is part of a large team headed by Professor Phil O’Connell (Westmead Millennium Institute for Medical Research). The team’s grant is one of five awarded on 9 September by T1DCRN, with a total value of $14 million.


Notes for Editors

Type 1 diabetes
Type 1 diabetes affects over 120,000 Australians and incidence is increasing every year. Typically striking young people, it results in the destruction of insulin-producing cells in the pancreas by the individual’s own immune system. Individuals with Type 1 diabetes endure a daily regime of injections and finger-prick tests to avoid dangerous troughs and peaks in blood glucose. The condition is also associated with serious disease complications that dramatically shorten life expectancy. Unlike Type 2 diabetes, Type 1 cannot be prevented and is not associated in any way with obesity or lifestyle.

Islet transplantation therapy

Clinical islet transplantation involves the isolation of pancreatic islets of Langerhans from the pancreases of deceased organ donors. Islets are infused into the liver of a recipient via the portal vein. If the therapy is successful, cells within the islets begin to produce insulin in response to elevated blood glucose in the recipient.

Successful islet transplantation therapy can free individuals of the need for externally administered insulin, and as such it can be considered a cure. In individuals with ‘brittle’ Type 1 diabetes and hypoglycaemia unawareness, islet transplantation is an established procedure with well-documented efficacy. However, for most Type 1 diabetics, including children, the need for lifelong immunosuppressive medication following the therapy means that it is not a realistic treatment option.

Achieving immunological tolerance

One approach to making islet transplantation therapy more widely applicable is to achieve reliable immunological tolerance to introduced islets – in other words, to ensure that an individual’s immune system does not attack them. This approach would have the considerable advantage that islet recipients would be free from longterm immunosuppressive drug regimes. It could transform islet transplantation therapy into a realistic and feasible treatment option for the vast majority of Type 1 diabetics, including children.



Media enquiries:

Dr Meredith Ross

Science Media & Communications Coordinator

Garvan Institute of Medical Research

T: +61 (0) 2 9295 8128

M: +61 (0) 439 873 258